Immune Pharma begins phase II study of bertilimumab in ulcerative colitis patie

[nogutsnoglory]

Phase 2 studies on Bertillimumab are beginning on patients with moderate to severe ulcerative colitis.

"Bertilimumab is a first-in-class fully human monoclonal antibody targeting eotaxin-1, a chemokine small protein regulating eosinophilic inflammation."

http://www.pharmabiz.com/NewsDetails.aspx?aid=73935&sid=2